1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Piramal Enterprises Limited - Product Pipeline Review - 2014

Piramal Enterprises Limited - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 44 pages

Piramal Enterprises Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Piramal Enterprises Limited - Product Pipeline Review - 2014’, provides an overview of the Piramal Enterprises Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Piramal Enterprises Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Piramal Enterprises Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Piramal Enterprises Limited’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Piramal Enterprises Limited’s pipeline products

Reasons to buy

- Evaluate Piramal Enterprises Limited’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Piramal Enterprises Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Piramal Enterprises Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Piramal Enterprises Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Piramal Enterprises Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Piramal Enterprises Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Piramal Enterprises Limited - Product Pipeline Review - 2014
Table of Contents
Piramal Enterprises Limited Snapshot 5
Piramal Enterprises Limited Overview 5
Key Information 5
Key Facts 5
Piramal Enterprises Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Piramal Enterprises Limited - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Piramal Enterprises Limited - Pipeline Products Glance 11
Piramal Enterprises Limited - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Piramal Enterprises Limited - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Piramal Enterprises Limited - Drug Profiles 15
P-276 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
P-1736 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
P-1446 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
P-11187 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
P-2745 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
P-7435 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
P-3971 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
P-7170 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
P-979 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
PM-181104 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
PM-181108 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Small Molecule for Cancer 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Piramal Enterprises Limited - Pipeline Analysis 30
Piramal Enterprises Limited - Pipeline Products by Target 30
Piramal Enterprises Limited - Pipeline Products by Route of Administration 32
Piramal Enterprises Limited - Pipeline Products by Molecule Type 33
Piramal Enterprises Limited - Pipeline Products by Mechanism of Action 34
Piramal Enterprises Limited - Recent Pipeline Updates 36
Piramal Enterprises Limited - Dormant Projects 38
Piramal Enterprises Limited - Discontinued Pipeline Products 39
Discontinued Pipeline Product Profiles 39
P-1201 39
P-276 39
PM-181110 39
Small Molecule to Inhibit IL-6 for Inflammation 39
Small Molecules for Oncology 39
Piramal Enterprises Limited - Locations And Subsidiaries 40
Head Office 40
Other Locations and Subsidiaries 40
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables

Piramal Enterprises Limited, Key Information 5
Piramal Enterprises Limited, Key Facts 5
Piramal Enterprises Limited - Pipeline by Indication, 2014 7
Piramal Enterprises Limited - Pipeline by Stage of Development, 2014 9
Piramal Enterprises Limited - Monotherapy Products in Pipeline, 2014 10
Piramal Enterprises Limited - Phase II, 2014 11
Piramal Enterprises Limited - Phase I, 2014 12
Piramal Enterprises Limited - Preclinical, 2014 13
Piramal Enterprises Limited - Discovery, 2014 14
Piramal Enterprises Limited - Pipeline by Target, 2014 31
Piramal Enterprises Limited - Pipeline by Route of Administration, 2014 32
Piramal Enterprises Limited - Pipeline by Molecule Type, 2014 33
Piramal Enterprises Limited - Pipeline Products by Mechanism of Action, 2014 35
Piramal Enterprises Limited - Recent Pipeline Updates, 2014 36
Piramal Enterprises Limited - Dormant Developmental Projects,2014 38
Piramal Enterprises Limited - Discontinued Pipeline Products, 2014 39
Piramal Enterprises Limited, Other Locations 40
iramal Enterprises Limited, Subsidiaries 41

List of Figures

Piramal Enterprises Limited - Pipeline by Top 10 Indication, 2014 7
Piramal Enterprises Limited - Pipeline by Stage of Development, 2014 9
Piramal Enterprises Limited - Monotherapy Products in Pipeline, 2014 10
Piramal Enterprises Limited - Pipeline by Top 10 Target, 2014 30
Piramal Enterprises Limited - Pipeline by Top 10 Route of Administration, 2014 32
Piramal Enterprises Limited - Pipeline by Top 10 Molecule Type, 2014 33
Piramal Enterprises Limited - Pipeline Products by Top 10 Mechanism of Action, 2014 34

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global ...

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.